Bacil Pharma Board Approves ₹50 Crore Rights Issue

Bacil Pharma Limited has intimated BSE Limited about a scheduled meeting of its Board of Directors. The meeting is set for Thursday, 9th July 2026.

The primary agenda for the board meeting includes:

• Consideration and approval of a proposal to raise funds through a Rights Issue of equity shares to eligible equity shareholders. The aggregate amount for this fundraising is up to ₹50,00,00,000 (Rupees Fifty Crores Only). The issuance will be conducted in accordance with the Companies Act, 2013, the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable laws, subject to necessary statutory and regulatory approvals.
• Consideration of a proposal to increase the Authorised Share Capital of the Company, if required, to facilitate the proposed Rights Issue and ensure adequate headroom for the issuance of equity shares.
• Consideration of consequent alteration of the Capital Clause of the Memorandum of Association and other related documents, subject to approval from the Board and shareholders.
• Determination and approval of the detailed terms and conditions of the Rights Issue. This includes, but is not limited to, the issue size, rights entitlement ratio, issue price, record date, rights issue schedule, appointment of intermediaries, and the draft Letter of Offer.
• Discussion on the Appointment and Resignation of Directors.
• Discussion of any other matter incidental or connected with the proposed Rights Issue and increase in Authorised Share Capital.

Furthermore, the company confirmed the continuation of the earlier intimated closure of the Trading Window. Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Conduct, the Trading Window for dealing in the company's securities remains closed for all designated persons and their immediate relatives. The closure is effective until 48 hours after the declaration of the outcome of the aforementioned Board Meeting.

The disclosure is signed by Mrs. Chaitali Kalpataru Shah, Director & CFO (DIN: 11167778), and is addressed to The General Manager, Listing Department, BSE Limited.